Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa kolutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
In this brief commentary, the renowned cardiologist Dr Mark Petrie from Glasgow, UK, provides an overview of the close association of type 2 diabetes and CV disease and summaries latest clinical data on CV risk reduction with GLP-1 RAs abd SGLT2 inhibators as presented at ESC 2020. He puts these findings into context with the most recent ESC/EASD guidelines on the recommend use of these newer glucose-lowering drugs in patients with T2D and established or high risk for CV disease.
He then explores the current under-utilization of GLP-1 RAs and suggests solutions how to overcome some of these obstacles in clinical practice.
Made for: Diabetologists, Endocrinologists, Cardiologists, Primary Care Physicians
Disease areas: Diabetes, Cardiovascular Disease
Developed by: Medscape
